Cited by 410Gastrointestinal motility and disordersEnhanced Recovery After SurgeryPelvic floor disorders treatments

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

Open access

Prather, Charlene M., Camilleri, Michael, Zinsmeister, Alan R., McKinzie, Sanna, Thomforde, George·2000·Gastroenterology

DOI 10.1016/s0016-5085(00)70251-4

Open this paper in CoChat — free account Open PDF

Abstract

Background & aims This study evaluated the effects of a partial 5-hydroxytryptamine (5-HT)(4) agonist, tegaserod, on gastric small bowel and colonic transit in constipation-predominant irritable bowel syndrome (IBS).Methods After a 1 week run-in period, 24 patients with constipation-predominant IBS were randomized to 1 week of tegaserod, 2 mg twice daily, or placebo treatment. Scintigraphic gastric emptying, small bowel transit, and colonic transit were determined before administration of study drug and after 1 week on the medication. Colonic transit was also measured using radiopaque markers and a single radiograph on day 5.Results Gastric emptying was unaltered by tegaserod. Proximal colonic filling at 6 hours, a measure of orocecal transit, was accelerated by tegaserod (70.4% +/- 1.3% [mean +/- SEM] vs. placebo, 46.4 +/- 1.9; P = 0.015). Proximal colonic emptying half-time and geometric center at 48 hours were also accelerated by tegaserod compared with baseline, but not compared with placebo. Mean colonic transit time was similar in both groups at baseline and after drug administration (tegaserod, 59.5 +/- 2.1 hours; placebo, 62.1 +/- 2.1 hours).Conclusions Tegaserod accelerates orocecal transit, tends to accelerate colonic transit, and deserves further study in patients with constipation-predominant IBS.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/s0016-5085(00)70251-4

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Simplified assessment of segmental colonic transit
Metcalf, A. M., Phillips, S. F., Zinsmeister, A. R., MacCarty, R. L., Beart, R. W., & Wolff, B. G. (1987) · Gastroenterology · doi:10.1016/0016-5085(87)90837-7 · Cited by 928
Self-citation
Capacity of the human colon to absorb fluid
Debongnie, J. C., & Phillips, S. F. (1978) · Gastroenterology · doi:10.1016/0016-5085(78)90246-9 · Cited by 416
Irritable bowel syndrome: relationship of disorders in the transit of a single solid meal to symptom patterns.
Cann, P. A., Read, N. W., Brown, C., Hobson, N., & Holdsworth, C. D. (1983) · Gut · doi:10.1136/gut.24.5.405 · Cited by 365
5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine
Grider, J. R., Foxx–Orenstein, A. E., & Jin, J. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70203-3 · Cited by 349
Bran and irritable bowel syndrome: time for reappraisal
Francis, C. Y. (1994) · The Lancet · doi:10.1016/s0140-6736(94)91055-3 · Cited by 315
Scintigraphic measurement of regional gut transit in idiopathic constipation.
Stivland, T., Camilleri, M., Vassallo, M., Proano, M., Rath, D. M., Brown, M. L., Thomforde, G., Pemberton, J., & Phillips, S. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90466-x · Cited by 272
Self-citation
Cisapride
Wiseman, L. R., & Faulds, D. M. (1994) · Drugs · doi:10.2165/00003495-199447010-00008 · Cited by 243
Human gastric emptying and colonic filling of solids characterized by a new method
Camilleri, M., Colemont, L. J., Phillips, S. F., Brown, M. L., Thomforde, G. M., Chapman, N., & Zinsmeister, A. R. (1989) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1989.257.2.g284 · Cited by 227
Self-citation
Selective stimulation of colonic transit by the benzofuran 5HT4 agonist, prucalopride, in healthy humans
Bouras, E. P., Camilleri, M., Burton, D., & Mckinzie, S. (1999) · Gut · doi:10.1136/gut.44.5.682 · Cited by 225
Self-citation
Towards a less costly but accurate test of gastric emptying and small bowel transit
Camilleri, M., Zinsmeister, A. R., Greydanus, M. P., Brown, M. L., & Proano, M. (1991) · Digestive Diseases and Sciences · doi:10.1007/bf01297027 · Cited by 198
Self-citation

Show all 22 references

Research works printed but not linked: 3

Pfannkuche, 1995, The properties of a new prokinetically active drug, SDZ HTF 919, Neurogastroenterol Motil, 7, 280
Langaker, 1998, The partial 5-HT4 agonist (HTF 919) improves symptoms in constipation-predominant irritable bowel syndrome, Digestion, 59, 20
Thompson, 1992, Functional bowel disease and functional abdominal pain, Gastroenterol Int, 5, 75

Sorted by citations

Items 101–200 of 410

Pharmacological management of constipation
Emmanuel, A. V., Tack, J. F., Quigley, E. M. M., & Talley, N. J. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01403.x · Cited by 75
Irritable Bowel Syndrome
Andresen, V., & Camilleri, M. (2006) · Drugs · doi:10.2165/00003495-200666080-00004 · Cited by 77
Self-citation
Challenges to the Therapeutic Pipeline for Irritable Bowel Syndrome: End Points and Regulatory Hurdles
Camilleri, M., & Chang, L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.005 · Cited by 74
Self-citation
Review article: the overlap between functional dyspepsia and irritable bowel syndrome — a tale of one or two disorders?
Cremonini, F., & Talley, N. (2004) · Alimentary Pharmacology and Therapeutics · doi:10.1111/j.1365-2036.2004.02184.x · Cited by 80
Abnormal Colonic Propagated Activity in Patients with Slow Transit Constipation and Constipation-Predominant Irritable Bowel Syndrome
Bassotti, G., Chistolini, F., Marinozzi, G., & Morelli, A. (2003) · Digestion · doi:10.1159/000075554 · Cited by 73
Review article: the treatment of functional abdominal bloating and distension: Review: treatment of bloating and distension
Schmulson, M., & Chang, L. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04637.x · Cited by 70
Diagnosis and treatment of chronic gastroparesis and chronic intestinal pseudo-obstruction
Smith, D. S., Williams, C. S., & Ferris, C. D. (2003) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(03)00028-1 · Cited by 71
Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects
Morganroth, J., Rüegg, P. C., Dunger‐Baldauf, C., Appel‐Dingemanse, S., Bliesath, H., & Lefkowitz, M. P. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05986.x · Cited by 70
The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high‐resolution manometry and videofluoroscopy
Fox, M. R., Menne, D., STUTZ, B., Fried, M., & Schwizer, W. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.03090.x · Cited by 69
Prokinetics in the Management of Functional Gastrointestinal Disorders
Quigley, E. M. M. (2015) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm15094 · Cited by 69
Promotility Medications – Now and in the Future
Karamanolis, G., & Tack, J. F. (2006) · Digestive Diseases · doi:10.1159/000092883 · Cited by 67
The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying
Futagami, S., Iwakiri, K., Shindo, T., Kawagoe, T., Horie, A., Shimpuku, M., Tanaka, Y., Kawami, N., Gudis, K., & Sakamoto, C. (2009) · Journal of Gastroenterology · doi:10.1007/s00535-009-0173-0 · Cited by 67
A randomized, controlled, double-blind trial of the adjunct use of tegaserod in whole-dose or split-dose polyethylene glycol electrolyte solution for colonoscopy preparation
Abdul-Baki, H. A., Hashash, J. G., Hajj, I. I. E., Azar, C. R., Zahabi, L. E., Mourad, F. H., Barada, K. A., & Sharara, A. I. (2008) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2008.01.044 · Cited by 66
Chronic pelvic pain
Baranowski, A. P. (2009) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2009.04.013 · Cited by 67
Updates on treatment of irritable bowel syndrome
Hammerle, C. W., & Surawicz, C. M. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.2639 · Cited by 65
Identification of neurons that express 5-hydroxytryptamine4 receptors in intestine
Poole, D. P., Xu, B., Koh, S. L., Hunne, B., Coupar, I. M., Irving, H. R., Shinjo, K., & Furness, J. B. (2006) · Cell and Tissue Research · doi:10.1007/s00441-006-0181-9 · Cited by 64
Tegaserod‐Induced Myocardial Infarction: Case Report and Hypothesis
Busti, A. J., Murillo, J. R., & Cryer, B. (2004) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.24.5.526.33351 · Cited by 64
Systematic Review on the Management of Chronic Constipation in North America
Brandt, L. J., Prather, C. M., Quigley, E. M. M., Schiller, L. R., Schoenfeld, P., & Talley, N. J. (2005) · The American Journal of Gastroenterology · doi:10.14309/00000434-200507001-00002 · Cited by 63
Self-citation
The in vitro pharmacological profile of TD-5108, a selective 5-HT4 receptor agonist with high intrinsic activity
Smith, J. A. M., Beattie, D. T., Marquess, D. G., Shaw, J. P., Vickery, R. G., & Humphrey, P. P. A. (2008) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-008-0282-y · Cited by 62
Tegaserod for Female Patients Suffering From IBS With Mixed Bowel Habits or Constipation: A Randomized Controlled Trial
Chey, W. D., Paré, P., Viegas, A., Ligozio, G., & Shetzline, M. A. (2008) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2008.01808.x · Cited by 63
Irritable Bowel Syndrome: Current Approach to Symptoms, Evaluation, and Treatment
Videlock, E. J., & Chang, L. (2007) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2007.07.002 · Cited by 60
Measurement of Gastrointestinal and Colonic Motor Functions in Humans and Animals
Camilleri, M., & Linden, D. (2016) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2016.04.003 · Cited by 55
Self-citation
Gastric Motility Disorders
Bouras, E. P., & Scolapio, J. S. (2004) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200408000-00003 · Cited by 61
Serotonergic modulating drugs for functional gastrointestinal diseases
Spiller, R. E. (2002) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2002.01612.x · Cited by 60
SLOW TRANSIT CONSTIPATION
Bharucha, A. E., & Phillips, S. F. (2001) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70168-0 · Cited by 60
Role of motility in chronic diarrhoea
Spiller, R. E. (2006) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00836.x · Cited by 61
Management of Chronic Constipation in the Elderly
Gallagher, P., O’Mahony, D., & Quigley, E. M. M. (2008) · Drugs & Aging · doi:10.2165/00002512-200825100-00001 · Cited by 60
Rationale for using serotonergic agents to treat irritable bowel syndrome
Baker, D. E. (2005) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/62.7.700 · Cited by 59
Activation of peripheral 5‐HT4receptors attenuates colonic sensitivity to intraluminal distension
Meerveld, B. G., Venkova, K. M., Hicks, G. A., Dennis, E., & Crowell, M. D. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00723.x · Cited by 59
Clinical Pharmacokinetics of Tegaserod, a Serotonin 5-HT4 Receptor Partial Agonist with Promotile Activity
Appel‐Dingemanse, S. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241130-00002 · Cited by 59
Effects of serotonin on intestinal secretion and motility
Spiller, R. E. (2001) · Current Opinion in Gastroenterology · doi:10.1097/00001574-200103000-00001 · Cited by 57
Role of prucalopride, a serotonin (5-HT4) receptor agonist, for the treatment of chronic constipation
Camilleri, M. (2010) · Clinical and Experimental Gastroenterology · doi:10.2147/ceg.s8091 · Cited by 57
Self-citation
In vitro metabolism of tegaserod in human liver and intestine: assessment of drug interactions.
Vickers, A. E. M., Zollinger, M., Dannecker, R., Tynes, R. E., Heitz, F., & Fischer, V. (2001) · PubMed · Cited by 55
Gastrointestinal motility in acute illness
Fruhwald, S. M., Holzer, P. D., & Metzler, H. (2008) · Wiener klinische Wochenschrift · doi:10.1007/s00508-007-0920-2 · Cited by 54
Scintigraphic Biomarkers for Colonic Dysmotility
Camilleri, M. (2010) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.23 · Cited by 54
Self-citation
Impaired intestinal gas propulsion in manometrically proven dysmotility and in irritable bowel syndrome
Serra, J., Villòria, A., Azpiroz, F., Lobo, B., Santos, J., Accarino, A. M., & Malagelada, J. R. (2009) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01447.x · Cited by 54
Cystic fibrosis and the role of gastrointestinal outcome measures in the new era of therapeutic CFTR modulation
Bodewes, F. A. J. A., Verkade, H. J., Taminiau, J. A. J. M., Borowitz, D., & Wilschanski, M. A. (2015) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2015.01.006 · Cited by 55
Regional gastric contractility alterations in a diabetic gastroparesis mouse model: effects of cholinergic and serotoninergic stimulation
James, A. N., Ryan, J. P., Crowell, M. D., & Parkman, H. P. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00431.2003 · Cited by 51
New insights into the pathophysiology of irritable bowel syndrome: Implications for future treatments
Crowell, M. D., Harris, L. A., Jones, M. P., & Chang, L. (2005) · Current Gastroenterology Reports · doi:10.1007/s11894-005-0019-8 · Cited by 50
Effect of a glucagon-like peptide 1 analog, ROSE-010, on GI motor functions in female patients with constipation-predominant irritable bowel syndrome
Camilleri, M., Vázquez‐Roque, M. I., Iturrino, J., Boldingh, A., Burton, D. B., McKinzie, S., Wong, B. S., Rao, A. S., Kenny, E., Månsson, M., et al. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00076.2012 · Cited by 50
Self-citation
Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation‐predominant irritable bowel syndrome and functional constipation
Neri, L., Iovino, P., & the Laxative Inadequate Relief Survey (LIRS) Group (2016) · Neurogastroenterology & Motility · doi:10.1111/nmo.12758 · Cited by 49
Naloxone treatment for irritable bowel syndrome — a randomized controlled trial with an oral formulation
Hawkes, N., Rhodes, J., Evans, B. K., Rhodes, P., Hawthorne, A. B., & Thomas, G. A. O. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01320.x · Cited by 49
Delivery of enteric neural progenitors with 5-HT4 agonist-loaded nanoparticles and thermosensitive hydrogel enhances cell proliferation and differentiation following transplantation in vivo
Hotta, R., Cheng, L. S., Graham, H. K., Nagy, N., Belkind‐Gerson, J., Mattheolabakis, G., Amiji, M. M., & Goldstein, A. M. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.02.016 · Cited by 48
Irritable bowel syndrome: toward a cost-effective management approach.
Martin, R., Barron, J. J., & Zacker, C. (2001) · PubMed · Cited by 46
Chronic intestinal pseudo-obstruction
Panganamamula, K. V., & Parkman, H. P. (2005) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-005-0046-4 · Cited by 48
Clinical practice guidelines for irritable bowel syndrome in Korea, 2017 revised edition
Song, K. H., Jung, H.-K., Kim, H. J., Koo, H. S., Kwon, Y. H., Shin, H. D., Lim, H. C., Shin, J. E., Kim, S. E., Cho, D. H., et al. (2018) · Journal of Neurogastroenterology and Motility · doi:10.5056/jnm17145 · Cited by 47
Serotonin receptor modulators in the treatment of irritable bowel syndrome
Lackner, J. (2008) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s140 · Cited by 47
Sigmoid‐colonic motility in health and irritable bowel syndrome: a role for 5‐hydroxytryptamine
Houghton, L. A., Atkinson, W., Lockhart, S., Fell, C., Whorwell, P. J., & Keevil, B. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2007.00943.x · Cited by 46
Pharmacology of the New Treatments for Lower Gastrointestinal Motility Disorders and Irritable Bowel Syndrome
Camilleri, M. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.261 · Cited by 47
Self-citation
Tegaserod
Lacy, B. E., & Yu, S. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200201000-00006 · Cited by 45
Symptomatic therapy in multiple sclerosis
Frohman, T. C., Castro, W., Shah, A. R., Courtney, A., Ortstadt, J., Davis, S. L., Logan, D., Abraham, T., Abraham, J., Remington, G. M., et al. (2011) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285611400658 · Cited by 44
Effect of Mosapride on Recovery of Intestinal Motility After Hand-Assisted Laparoscopic Colectomy for Carcinoma
Narita, K., Tsunoda, A., Takenaka, K., Watanabe, M., Nakao, K., & Kusano, M. (2008) · Diseases of the Colon & Rectum · doi:10.1007/s10350-008-9407-0 · Cited by 44
The Pharmacology of TD-8954, a Potent and Selective 5-HT4 Receptor Agonist with Gastrointestinal Prokinetic Properties
Beattie, D. T., Armstrong, S. R., Vickery, R. G., Tsuruda, P. R., Campbell, C. B., Richardson, C. L., McCullough, J. L., Daniels, O., Kersey, K., Li, Y.-P., et al. (2011) · Frontiers in Pharmacology · doi:10.3389/fphar.2011.00025 · Cited by 44
Prokinetics in the Management of Functional Gastrointestinal Disorders
Quigley, E. M. M. (2017) · Current Gastroenterology Reports · doi:10.1007/s11894-017-0593-6 · Cited by 44
Heat-killed Lactobacillus casei subsp. casei 327 promotes colonic serotonin synthesis in mice
Hara, T., Mihara, T., Ishibashi, M., Kumagai, T., & Joh, T. (2018) · Journal of Functional Foods · doi:10.1016/j.jff.2018.05.050 · Cited by 42
CONSTIPATION AND FECAL INCONTINENCE IN THE ELDERLY
Schiller, L. R. (2001) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(05)70192-8 · Cited by 42
Tegaserod
Wagstaff, A. J., Frampton, J. E., & Croom, K. F. (2003) · Drugs · doi:10.2165/00003495-200363110-00013 · Cited by 42
Diabetes and the Small Intestine
Gotfried, J., Priest, S., & Schey, R. (2017) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-017-0155-x · Cited by 45
Tegaserod is effective in the initial and retreatment of irritable bowel syndrome with constipation
Müller-Lissner, S. A., Holtmann, G., Rueegg, P. C., Weidinger, G., & Löffler, H. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02294.x · Cited by 41
Associations of tryptophan hydroxylase gene polymorphisms with irritable bowel syndrome
Jun, S., Kohen, R., Cain, K. C., Jarrett, M. E., & Heitkemper, M. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01623.x · Cited by 41
Drug Development for the Irritable Bowel Syndrome: Current Challenges and Future Perspectives
Ponti, F. D. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00007 · Cited by 40
The role of experimental models in developing new treatments for irritable bowel syndrome
Holschneider, D. P., Bradesi, S., & Mayer, E. A. (2011) · Expert Review of Gastroenterology & Hepatology · doi:10.1586/egh.10.88 · Cited by 40
Review of the implications of dietary tryptophan intake in patients with irritable bowel syndrome and psychiatric disorders
Agazzi, A., Ponti, F. D., GIORGIO, R. D., Candura, S. M., Anselmi, L., Cervio, E., Nucci, A. D., & Tonini, M. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00277-9 · Cited by 39
Systematic review and network meta‐analysis: efficacy of licensed drugs for abdominal bloating in irritable bowel syndrome with constipation
Nelson, A. D., Black, C. J., Houghton, L. A., Lugo‐Fagundo, N. S., Lacy, B. E., & Ford, A. C. (2021) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16437 · Cited by 39
Chronic intestinal pseudoobstruction
Lyford, G., & Foxx–Orenstein, A. E. (2004) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-004-0018-0 · Cited by 39
Efficacy of Current Drug Therapies in Irritable Bowel Syndrome: What Works and Does Not Work
Schoenfeld, P. (2005) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2005.02.002 · Cited by 39
Elobixibat for the treatment of constipation
Wong, B., & Camilleri, M. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.753056 · Cited by 47
Self-citation
Selected Interventions in Nuclear Medicine: Gastrointestinal Motor Functions
Odunsi, S. T., & Camilleri, M. (2009) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2008.11.002 · Cited by 37
Self-citation
Effect of tegaserod on colonic transit time in male patients with constipation‐predominant irritable bowel syndrome
Harish, K., Hazeena, K., Thomas, V., Kumar, S., Jose, T., & Narayanan, P. (2007) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2006.04543.x · Cited by 38
Low-dose nocturnal tegaserod or erythromycin delays symptom recurrence after treatment of irritable bowel syndrome based on presumed bacterial overgrowth.
Pimentel, M., Morales, W., Lezcano, S., Dai, S.-C., Low, K., & Yang, J. M. (2009) · PubMed Central · Cited by 37
Lack of Association of Tegaserod With Adverse Cardiovascular Outcomes in a Matched Case-Control Study
Anderson, J. L., May, H. T., Bair, T. L., Muhlestein, J. B., Horne, B. D., & Carlquist, J. F. (2009) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248409340158 · Cited by 37
Biomarkers in IBS: when will they replace symptoms for diagnosis and management?: Table 1
Barbara, G., & Stanghellini, V. (2009) · Gut · doi:10.1136/gut.2008.169672 · Cited by 37
A double‐blind, randomized, placebo‐controlled trial of itopride (100 and 200 mg three times daily) on gastric motor and sensory function in healthy volunteers
Choung, R. S., Talley, N. J., Peterson, J. M., Camilleri, M., Burton, D. D., Harmsen, W. S., & Zinsmeister, A. R. (2007) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2006.00869.x · Cited by 37
Self-citation
Safety and tolerability of tegaserod in patients with irritable bowel syndrome and diarrhea symptoms
Fidelholtz, J., Smith, W., Rawls, J., Shi, Y., Zack, A., Rüegg, P. C., & Lefkowitz, M. P. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05692.x · Cited by 37
Diagnosis and treatment of irritable bowel syndrome: State of the art
Tillisch, K., & Chang, L. (2005) · Current Gastroenterology Reports · doi:10.1007/s11894-005-0016-y · Cited by 36
Pharmacotherapy for intestinal motor and sensory disorders
Hasler, W. L. (2003) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(03)00027-x · Cited by 36
Dose-response effect of a β3-adrenergic receptor agonist, solabegron, on gastrointestinal transit, bowel function, and somatostatin levels in health
Grudell, A., Camilleri, M., Jensen, K. L., Foxx–Orenstein, A. E., Burton, D. D., Ryks, M. D., Baxter, K. L., Cox, D. S., Dukes, G. E., Kelleher, D. L., et al. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00051.2008 · Cited by 33
Self-citation
Effects of a 5‐HT4 receptor agonist on oesophageal function and gastro‐oesophageal reflux: studies using combined impedance‐manometry and combined impedance‐pH
Tutuian, R. I., Mainie, I., Allan, R., Hargreaves, K., AGRAWAL, A., Freeman, J., Gale, J. D., & Castell, D. O. (2006) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2006.02968.x · Cited by 35
Tegaserod for the Treatment of Irritable Bowel Syndrome
Madia, V. N., Messore, A., Saccoliti, F., Tudino, V., Leo, A. D., Vita, D. D., Bortolami, M., Scipione, L., Pindinello, I., Costi, R., et al. (2019) · Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry · doi:10.2174/1871523018666190911121306 · Cited by 34
Alterations of sensori-motor functions of the digestive tract in the pathophysiology of irritable bowel syndrome
Delvaux, M. M. (2004) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2004.06.004 · Cited by 34
Tegaserod maleate in the treatment of irritable bowel syndrome: A clinical review
Rivkin, A. M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80198-4 · Cited by 33
Un consenso latinoamericano sobre el síndrome del intestino irritable
Valenzuela, J. E., Alvarado, J., Cohen, H., Damiao, A. O., Francisconi, C. F. D. M., Frugone, L., González, J. C., Hernández, A., Iade, B., Lopes, M. H., et al. (2004) · Gastroenterología y Hepatología · doi:10.1016/s0210-5705(03)70470-1 · Cited by 33
The effects of tegaserod, a 5‐HT4 receptor agonist, on gastric emptying in a murine model of diabetes mellitus
Crowell, M. D., Mathis, C., Schettler, V. A., Yunus, T. S., & Lacy, B. E. (2005) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2005.00681.x · Cited by 33
Irritable bowel syndrome with constipation: a European-focused systematic literature review of disease burden
Fortea, J., & Prior, M. (2013) · Journal of Medical Economics · doi:10.3111/13696998.2012.756397 · Cited by 33
Therapeutic potential of serotonin 4 receptor for chronic depression and its associated comorbidity in the gut
Agrawal, L., Korkutata, M., Vimal, S. K., Yadav, M. K., Bhattacharyya, S., & Shiga, T. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.107969 · Cited by 32
Aktualisierte S2k-Leitlinie chronische Obstipation der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie & Motilität (DGNM) – April 2022 – AWMF-Registriernummer: 021–019
Andresen, V., Pehl, C., Becker, G., Frieling, T., Goebel‐Stengel, M., Gundling, F., Herold, A., Karaus, M., Keller, J., Kim, M., et al. (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-1928 · Cited by 32
Tegaserod for Irritable Bowel Syndrome With Constipation in Women Younger Than 65 Years Without Cardiovascular Disease: Pooled Analyses of 4 Controlled Trials
Shah, E. D., Lacy, B. E., Chey, W. D., Chang, L., & Brenner, D. M. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001313 · Cited by 31
Options for patients with irritable bowel syndrome: contrasting traditional and novel serotonergic therapies
Johanson, J. F. (2004) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2004.00550.x · Cited by 31
Pseudo-obstruction intestinale chronique
Joly, F., Amiot, A., Coffin, B., Lavergne‐Slove, A., Messing, B., & Bouhnik, Y. (2006) · Gastroentérologie Clinique et Biologique · doi:10.1016/s0399-8320(06)73359-0 · Cited by 31
Serotonergic agents and the irritable bowel syndrome: what goes wrong?
Spiller, R. E. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.003 · Cited by 30
Desensitization of the peristaltic reflex induced by mucosal stimulation with the selective 5-HT4agonist tegaserod
Grider, J. R. (2005) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00326.2005 · Cited by 30
Comparison of pyridostigmine and bisacodyl in the treatment of refractory chronic constipation.
Soufi-Afshar, I., Moghadamnia, A. A., Bijani, A., Kazemi, S., & Shokri‐Shirvani, J. (2016) · Europe PMC (PubMed Central) · Cited by 29
Safety, Tolerability, and Efficacy of Tegaserod over 13 Months in Patients with Chronic Constipation
Müller-Lissner, S. A., Kamm, M. A., Musoğlu, A., Earnest, D. L., Dunger‐Baldauf, C., & Shetzline, M. A. (2006) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2006.00789.x · Cited by 29
Review article: the safety profile of tegaserod
Schoenfeld, P. (2004) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2004.02182.x · Cited by 28
Safety and Tolerability of Tegaserod in Patients With Chronic Constipation: Pooled Data From Two Phase III Studies
Quigley, E. M. M., Wald, A. M., Fidelholtz, J., Boivin, M., Pecher, E., & Earnest, D. (2006) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2006.02.017 · Cited by 28
Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom
Layer, P., Keller, J., Löffler, H., & Kreiss, A. (2007) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.2007.3.1.107 · Cited by 28
Irritable bowel syndrome: an update on therapeutic modalities
Farhadi, A., Bruninga, K., Fields, J. Z., & Keshavarzian, A. (2001) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.10.7.1211 · Cited by 27
Pharmacologic treatment of constipation: what is new?
Pohl, D., Tutuian, R. I., & Fried, M. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.008 · Cited by 26
Nuclear Scintigraphy in Practice: Gastrointestinal Motility
Sólnes, L. B., Sheikhbahaei, S., & Ziessman, H. A. (2018) · American Journal of Roentgenology · doi:10.2214/ajr.18.19787 · Cited by 26
Irritable Bowel Syndrome: Update on Pathogenesis and Management
Alaradi, O., & Barkin, J. S. (2002) · Medical Principles and Practice · doi:10.1159/000048654 · Cited by 25

Authors: Prather, C. M., Camilleri, M., Zinsmeister, A. R., McKinzie, S., & Thomforde, G.
Affiliations: Mayo Clinic (US)
ORCID: Camilleri, Michael
Venue: Gastroenterology
Publisher: Elsevier BV
Published: 2000-03
Volume: 118
Issue: 3
Pages: 463-468
ISSN: 0016-5085 (ISSN-L)
DOI: 10.1016/s0016-5085(00)70251-4
OpenAlex: W2095055104
Cited by: 410
References: 22
Citations by year: 2026: 1 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 2 · 2021: 6 · 2020: 6 · 2019: 5 · 2018: 7 · 2017: 4 · 2016: 8 · 2015: 7 · 2014: 4 · 2013: 6 · 2012: 12
FWCI: 36.61
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Gastroenterology (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases (K24DK02638-01, K24DK002638, R01-DK546881)
National Center for Research Resources (RR-00585, M01RR000585)
Topics: Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
Health Sciences › Medicine › Surgery › Enhanced Recovery After Surgery
Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
Keywords: tegaserod, irritable bowel syndrome with constipation, orocecal transit, colonic transit, gastric emptying, small intestinal transit, 5-HT4 receptor agonist, scintigraphy, radiopaque markers
MeSH terms: Adult, Aged, Colon, Colonic Diseases, Functional, Constipation, Double-Blind Method, Gastrointestinal Transit, Guanidines, Humans, Indoles, Intestine, Small, Middle Aged, Radionuclide Imaging, Stomach, Time Factors, Serotonin Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tegaserod accelerates orocecal transit in patients with constipation-predominant irritable bowel syndrome

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks